ABBVIE

AbbVie announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody, in adult patients with diffuse large B-cell lymphoma (DLBCL) at the 66th ASH Annual Meeting. The Phase 1b/2 EPCORE NHL-2 trial showed an overall response rate (ORR) of 100% and a complete response (CR) rate of 87% in high-risk DLBCL patients. The Phase 2 EPCORE NHL-1 trial, evaluating epcoritamab monotherapy in relapsed or refractory large B-cell lymphoma (LBCL) patients, showed a CR rate of 41% with an estimated 52% still responding at three years.

The article discusses the importance of enabling JavaScript for optimal app performance.

AbbVie announced positive Phase 3 trial results for tavapadon, a Parkinson's disease treatment, meeting primary and secondary endpoints. The company plans to seek FDA approval in 2025.

Terry Pirovolakis developed a gene therapy for his son's ultra-rare disease SPG50 and founded Elpida Therapeutics to help other families. AbbVie's tavapadon showed success in another Parkinson's Phase 3 trial. The BIOSECURE Act, aimed at preventing U.S. biopharma companies from working with Chinese 'companies of concern,' was excluded from the defense budget bill. President-elect Trump echoed Robert F. Kennedy Jr.'s vaccine skepticism. A study highlighted disparities in bone marrow transplant access based on socioeconomic status.

AbbVie announces positive Phase 3 TEMPO-2 trial results for tavapadon, a D1/D5 partial agonist, showing significant improvement in MDS-UPDRS Parts II and III scores at week 26, meeting primary and key secondary endpoints. AbbVie plans to submit an NDA to the FDA in 2025.

Tavapadon met primary and secondary endpoints in Phase 3 TEMPO-2 trial, showing significant improvement in MDS-UPDRS Parts II and III scores at week 26, supporting its potential as a first-in-class D1/D5 partial agonist for Parkinson's disease. AbbVie plans to submit an NDA to the FDA in 2025.

The article discusses the importance of enabling JavaScript for optimal app performance.

Disc Medicine presented positive Phase 1b trial results of DISC-0974 in MF anemia patients at ASH 2024, showing durable hematologic response across subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapy. A Phase 2 study in MF anemia has been initiated.